English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

The aim of this study was to evaluate the synchronization rate, ease to parturition, calves viability and retained placenta rate for Nellore recipients treated with triancinolone (TRI) + dexametasone (DEXA) + PGF 2 α (d-CLO). Hundred-ninety-four crossbred recipients (½ Nellore/ ½ Caracu) were divided into two groups (TRI, n = 97; Control, n = 97) and observed from 285 to 292 days of pregnancy. On Day 285, animals from Group TRI received 1mg/60 Kg of BW/IM of triancinolone (Retardoesteroide ® , Hertape Calier Saude Animal S/A) followed of association of 25mg of dexametasone (Caliercortin ® , Hertape Calier Saude Animal S/A) and 150μg of D-cloprostenol (Veteglan ® , Hertape Calier Saude Animal S/A) on Day 292. Animals from Control received injections of saline solution in same days. TRI had higher synchronization of parturition than Control (79.4% vs. 19.5, respectively; P < 0.05), as well TRI had lower assistance of parturition. No differences were observed for assistance of parturition comparing the born weight and gender of calves. TRI had lesser placenta retained than Control (11.4% vs. 25.8%, respectively; P < 0.05). In short, this strategy of induction resulted in better conditions of assistance and quality of parturition, decreasing the placenta retained in Nellore recipients implanted with embryos produced in vitro .

Strategy to improve the parturition ability in crossbred recipients implanted with embryos produced in vitro